Overview

Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma

Status:
Completed
Trial end date:
2016-10-13
Target enrollment:
Participant gender:
Summary
Phase II Study of Refametinib, a MEK inhibitor, as second-line treatment in advanced biliary tract adenocarcinoma
Phase:
Phase 2
Details
Lead Sponsor:
Samsung Medical Center